Toll Free: 1-888-928-9744

Fibrosis - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 151 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fibrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Fibrosis - Pipeline Review, H1 2015', provides an overview of the Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Fibrosis Overview 8 Therapeutics Development 9 Pipeline Products for Fibrosis - Overview 9 Pipeline Products for Fibrosis - Comparative Analysis 10 Fibrosis - Therapeutics under Development by Companies 11 Fibrosis - Therapeutics under Investigation by Universities/Institutes 15 Fibrosis - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Fibrosis - Products under Development by Companies 19 Fibrosis - Products under Investigation by Universities/Institutes 22 Fibrosis - Companies Involved in Therapeutics Development 23 Acceleron Pharma, Inc. 23 AiCuris GmbH & Co. KG 24 AnaMar AB 25 Arena Pharmaceuticals, Inc. 26 Bristol-Myers Squibb Company 27 Digna Biotech, S.L. 28 F. Hoffmann-La Roche Ltd. 29 FibroGen, Inc. 30 Five Prime Therapeutics, Inc. 31 Galectin Therapeutics, Inc. 32 GenKyoTex S.A. 33 GlycoMimetics, Inc. 34 HanAll Biopharma Co., Ltd. 35 Intercept Pharmaceuticals, Inc. 36 Isarna Therapeutics GmbH 37 KineMed, Inc. 38 Lycera Corp. 39 MandalMed, Inc. 40 miRagen Therapeutics, Inc. 41 Neumedicines Inc. 42 Pfizer Inc. 43 Promedior, Inc. 44 ProMetic Life Sciences Inc. 45 RuiYi Inc. 46 Scholar Rock, Inc. 47 Siena Biotech S.p.A. 48 SK Chemicals Co., Ltd. 49 Taisho Pharmaceutical Co., Ltd. 50 TRACON Pharmaceuticals, Inc. 51 UCB S.A. 52 Vericel Corporation 53 VivaCell Biotechnology Espana S.L. 54 Fibrosis - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Target 56 Assessment by Mechanism of Action 58 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 AIC-649 - Drug Profile 64 AMAP-102 - Drug Profile 65 Antibodies for Fibrosis - Drug Profile 67 Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile 68 APD-371 - Drug Profile 69 ASPH-0047 - Drug Profile 70 ASPH-1047 - Drug Profile 72 Biologics to Inhibit TGF-beta 1 for Fibrosis - Drug Profile 74 disitertide - Drug Profile 75 Drug to Modulate Galectin for Fibrosis, Inflammation and Cancer - Drug Profile 77 G-XXX - Drug Profile 78 Galectin-3C - Drug Profile 79 GC-4419 - Drug Profile 81 GKT-136901 - Drug Profile 82 HL-156FIB - Drug Profile 84 INT-767 - Drug Profile 85 ixmyelocel-T - Drug Profile 87 KBP-7018 - Drug Profile 90 MGN-4220 - Drug Profile 91 NCE-401 - Drug Profile 92 NMIL-121 - Drug Profile 93 noscapine - Drug Profile 95 NPH-09 - Drug Profile 96 P-006 - Drug Profile 97 PBI-4419 - Drug Profile 98 PF-06473871 - Drug Profile 99 Polysaccharides to Inhibit Galectin for Fibrosis, Inflammation and Cancer - Drug Profile 101 PRI-724 - Drug Profile 102 PRM-151 - Drug Profile 104 Protein for Fibrosis - Drug Profile 106 Proteins for Fibrosis - Drug Profile 107 Recombinant Protein to Inhibit BMP-1 like Proteinases for Fibrotic Disorders - Drug Profile 108 RYI-018 - Drug Profile 109 Small molecule for cancer and fibrotic disease - Drug Profile 110 Small Molecule for Fibrotic Diseases - Drug Profile 111 Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis - Drug Profile 112 Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases - Drug Profile 113 Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - Drug Profile 114 Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease - Drug Profile 115 Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile 116 Small Molecule to Inhibit Rho Kinase for Fibrosis - Drug Profile 117 Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology - Drug Profile 118 Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 119 Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis - Drug Profile 120 Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis - Drug Profile 121 Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile 122 Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 123 SphK2 Program - Drug Profile 124 TRC-205 - Drug Profile 125 Trophokine - Drug Profile 126 VCE-0048 - Drug Profile 127 Fibrosis - Recent Pipeline Updates 128 Fibrosis - Dormant Projects 142 Fibrosis - Discontinued Products 145 Appendix 146 Methodology 146 Coverage 146 Secondary Research 146 Primary Research 146 Expert Panel Validation 146 Contact Us 146 Disclaimer 147
List of Tables
Number of Products under Development for Fibrosis, H1 2015 13 Number of Products under Development for Fibrosis - Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 16 Number of Products under Development by Companies, H1 2015 (Contd..1) 17 Number of Products under Development by Companies, H1 2015 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2015 19 Comparative Analysis by Clinical Stage Development, H1 2015 20 Comparative Analysis by Early Stage Development, H1 2015 21 Comparative Analysis by Unknown Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Fibrosis - Pipeline by Acceleron Pharma, Inc., H1 2015 27 Fibrosis - Pipeline by AiCuris GmbH & Co. KG, H1 2015 28 Fibrosis - Pipeline by AnaMar AB, H1 2015 29 Fibrosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 30 Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 31 Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015 32 Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 33 Fibrosis - Pipeline by FibroGen, Inc., H1 2015 34 Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H1 2015 35 Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015 36 Fibrosis - Pipeline by GenKyoTex S.A., H1 2015 37 Fibrosis - Pipeline by GlycoMimetics, Inc., H1 2015 38 Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 39 Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 40 Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2015 41 Fibrosis - Pipeline by KineMed, Inc., H1 2015 42 Fibrosis - Pipeline by Lycera Corp., H1 2015 43 Fibrosis - Pipeline by MandalMed, Inc., H1 2015 44 Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015 45 Fibrosis - Pipeline by Neumedicines Inc., H1 2015 46 Fibrosis - Pipeline by Pfizer Inc., H1 2015 47 Fibrosis - Pipeline by Promedior, Inc., H1 2015 48 Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015 49 Fibrosis - Pipeline by RuiYi Inc., H1 2015 50 Fibrosis - Pipeline by Scholar Rock, Inc., H1 2015 51 Fibrosis - Pipeline by Siena Biotech S.p.A., H1 2015 52 Fibrosis - Pipeline by SK Chemicals Co., Ltd., H1 2015 53 Fibrosis - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 54 Fibrosis - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 55 Fibrosis - Pipeline by UCB S.A., H1 2015 56 Fibrosis - Pipeline by Vericel Corporation, H1 2015 57 Fibrosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 58 Assessment by Monotherapy Products, H1 2015 59 Number of Products by Stage and Target, H1 2015 61 Number of Products by Stage and Mechanism of Action, H1 2015 63 Number of Products by Stage and Route of Administration, H1 2015 65 Number of Products by Stage and Molecule Type, H1 2015 67 Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 132 Fibrosis - Dormant Projects, H1 2015 146 Fibrosis - Dormant Projects (Contd..1), H1 2015 147 Fibrosis - Dormant Projects (Contd..2), H1 2015 148 Fibrosis - Discontinued Products, H1 2015 149



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify